Annual Report FY26 and 33rd AGM notice on 30 September 2026

Revenue declinedRelated-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹73.50

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+0.4% vs market

Pharmaceuticals peers, median of 171sector+0.4%+0.3% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+0.3+0.4+0.4+0.3

Next day

-1.1+0.6-1.7+0.2-1.3

-2.4-0.4-2.1-0.1-2.4

—-0.9—-0.0—

-3.4-0.3-3.1+0.3-3.7

-0.8+0.3-1.1+0.8-1.6

+0.7+1.3-0.6+1.2-0.5

15d

-3.2-0.1-3.1+1.0-4.2

-0.7-1.2+0.6+0.0-0.7

+1.5-7.7+9.2-3.5+5.0

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ishita Drugs filed its 33rd Annual Report for FY 2025-26 with BSE. Revenue was Rs 1513.34 lakhs (down 1.30 percent) and net profit Rs 77.85 lakhs (down 10.32 percent) due to higher repair costs. No dividend as funds go to factory upgradation under new drug norms. AGM on 30 September 2026 covers auditor re-appointment, director Mrs Abha Agrawal re-appointment aged 75, and related party deals with Ishita Pharmaceuticals and Anvi Lifesciences.

Likely market impact

Revenue and profit declined. No dividend. Factory upgrade may lift earnings. Shareholders vote on related party deals and a director re-appointment.